Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Letrozole in combination with Bevacizumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: exemestane, pemetrexed disodium, carboplatin, laboratory biomarker analysis, pharmacological study, questionnaire administration, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vulvo Vaginal Atrophy
Interventions: Femarelle; Dietary Supplement
Lead sponsor: Dr. Lila Nachtigall Rapid Medical Research, New York; Other
Eligibility: 40 Years to 85 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Everolimus, Placebo; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 25
States / cities: Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more

Conditions: Advanced or Metastatic Breast Cancer
Interventions: LEE011, Buparlisib, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Lafayette, Indiana • Charleston, South Carolina + 2 more

Conditions: Postmenopausal Osteoporosis
Interventions: Alendronate, Ibandronate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 54
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tempe, Arizona + 47 more

Conditions: Healthy
Interventions: Fulvestrant; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions: Not listed
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more

Conditions: Breast Cancer
Interventions: 6 Gy/ fraction; Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Ovarian Failure, Infertility, Early Menopause And Infertility In Females After Treatment For Childhood Cancer
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Years to 35 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2041
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis
Interventions: ALX1-11 (drug); Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more

Conditions: Alzheimer Disease
Interventions: Donepezil, Estrogen, Progesterone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Post-menopausal Vasomotor Symptoms
Interventions: BAY3427080, Placebo (for BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: DeLand, Florida • Miami, Florida • San Antonio, Texas

Conditions: Menopause
Interventions: TSEC (Tissue-selective estrogen complexes), Placebo; Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 50 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Human Immunodeficiency Virus
Interventions: Dapivirine Vaginal Ring, Placebo Vaginal Ring; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL); Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions: D-Mannose, Placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions
Interventions: Haelan 951; Dietary Supplement
Lead sponsor: Spectrum Clinical Research, LLC; Network
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Breast Cancer
Interventions: letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more

Conditions: Menopause, Hot Flashes
Interventions: Shatavari (Asparagus racemosus) Extract, Placebo; Dietary Supplement · Other
Lead sponsor: India Glycols Ltd; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Healthy Volunteer Study
Interventions: SCO-120, matching placebo; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Dilworth, Minnesota • Creve Coeur, Missouri

Search by objective public record fields.

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer

A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers

Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy

Open Label Extension Study of PREOS

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Raising Insulin Sensitivity in Post Menopause

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects